KẾT QUẢ HÓA XẠ TRỊ TIỀN PHẪU UNG THƯ TRỰC TRÀNG GIAI ĐOẠN II, III

Abstract

Objectives: To evaluate the treatment results of preoperative concurrent chemoradiotherapy in stage II, III adenocarcinoma of the lower two-thirds of the rectum. Patients and methods: Retrospective study on 69 stage II, III middle-to-low rectal cancer patients underwent preoperative concurrent chemoradiotherapy at 108 Military Central Hospital between January 2020 and May 2021. Results: Mean age was 60.49 ± 10. Middle rectal cancer accounted for 58%. After chemoradiotherapy, 89.2% of patients had no longer hematochezia; 10 patients (14.5%) had no visible tumor on endoscopy. 95.4% of 66 patients who had undergone surgery had complete resection. Of 42 low rectal cancer, 30 (71.4%) underwent sphincter-preserving procedures. 11 patients (16.6%) had pathologic complete response. 59.1% had tumor regression, while 95.1% had response in nodal status. Common adverse events were diarrhea, skin inflammation, cystitis, most of which were in grade I. Conclusion: preoperative concurrent chemoradiotherapy achieved encouraging rates of tumor downstaging and sphincter preservation with a low toxicity profile.